# Bird Rock Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bird-rock-bio

- Industry: Pharmaceuticals
- Headquarters: US
- Total disclosed funding: $68M
- Latest round: Series B (Mar 27, 2014)
- Investors on record: 6

## About

Establised in 2006 and based in California, US, Bird Rock Bio is a clinical-stage biopharmaceutical company that offers antibody therapeutics for immuno-inflammatory diseases. In August 2023, Skye Bioscience, Inc. portfolio company of 5AM Ventures and Versant Ventures acquired Bird Rock Bio for USD 20 million.

Bird Rock Bio’s pipeline centered around Nimacimab, a therapeutic antibody designed to modulate immune and metabolic pathways. The company also developed a broader portfolio of monoclonal antibodies targeting G-protein coupled receptors (GPCRs), leveraging its proprietary discovery platform. These biologics were designed to offer improved specificity and efficacy over traditional small molecule drugs.

## Funding rounds

- Series B, Mar 27, 2014, $15M — Versant Ventures, Aravis, SR One, 5AM Ventures, Apposite Capital, M Ventures
- Series A, Mar 23, 2012, $15M — Versant Ventures, Aravis, SR One, 5AM Ventures, Apposite Capital, M Ventures
- Series A, May 14, 2009, $13M — Versant Ventures, SR One, 5AM Ventures, M Ventures
- Series A, Jan 7, 2009, $25M — Versant Ventures, 5AM Ventures, Apposite Capital

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Apposite Capital (https://capitalatlas.ai/funds/apposite-capital) — Series A, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B
- Aravis (https://capitalatlas.ai/funds/aravis) — Series A, Series B